Back

ARS Pharmaceuticals stock falls 23.9% as CVS Caremark coverage delay triggers lawsuit

Verifying
  • Robbins LLP announced a securities class action against ARS Pharmaceuticals for investors during the stated Class Period.
  • ARS stock fell from $10.54 to $8.02, a decline exceeding 23.9%, after the coverage update.
  • CVS Caremark reserved its expanded neffy coverage decision until January 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.